New Zealand Professional Investment Services Firm

Forsyth Barr

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

New Zealand Professional Investment Services Firm, Forsyth Barr

Equity Bottom-Up

<ul><li>Pacific Edge's (PEB) 4Q24 update all but confirmed the halt in momentum, with lab throughput down -19% versus 4Q23 and broadly flat versus 3Q24, despite 3Q being typically seasonally soft. </li><li>The update shows PEB is battening down the hatches well by appropriately managing its cost base and accelerating the clinical research development (including positive comments on the recently concluded STRATA study and potential Detect+ pricing).</li><li>PEB remains stuck in a holding pattern where it needs to continue to invest to: (1) drive improved clinical research (a necessity for longer-term Cxbladder adoption through guidelines inclusion), and (2) uphold a captive sales presence, despite the significant uncertainty on the revenue trajectory. </li></ul>

Pacific Edge's (PEB) 4Q24 update all but confirmed the halt in momentum, with lab throughput down -19% versus 4Q23 and broadly flat versus 3Q24, despite 3Q being typically seasonally soft. The update shows PEB is battening down the hatches well by appropriately managing its cost base and accelerating the clinical research development (including positive comments on the recently concluded STRATA study and potential Detect+ pricing).PEB remains stuck in a holding pattern where it needs to continue to invest to: (1) drive improved clinical research (a necessity for longer-term Cxbladder adoption through guidelines inclusion), and (2) uphold a captive sales presence, despite the significant uncertainty on the revenue trajectory. 

Pacific Edge - 4Q24 — Battening Down the Hatches